爱朋医疗(300753) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥64,821,886.38, a decrease of 26.13% compared to ¥87,752,962.00 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥17,649,164.17, representing a decline of 1,400.65% from a profit of ¥1,356,953.49 in the previous year[4] - Total operating revenue decreased to ¥64,821,886.38 from ¥87,752,962.00, representing a decline of approximately 26.1% year-over-year[19] - Net profit for the period was a loss of ¥18,570,429.48, compared to a profit of ¥1,127,308.15 in the previous period, indicating a significant downturn[22] - The weighted average return on equity was -2.55%, a decrease of 2.74% from 0.19% in the same period last year[4] - The company reported a basic and diluted earnings per share of -0.1400, compared to 0.0108 in the previous period, indicating a significant decline in profitability[22] Cash Flow and Liquidity - The net cash flow from operating activities improved by 40.37%, amounting to -¥38,197,292.23 compared to -¥64,053,023.05 in Q1 2024[4] - Cash received from sales of goods and services increased to ¥72,290,849.98 from ¥69,016,477.25, showing a growth of approximately 3.3%[23] - The net increase in cash and cash equivalents for the period was -$121,980,152.39, compared to -$152,951,984.98 in the previous period[24] - The beginning balance of cash and cash equivalents was $201,635,257.87, slightly up from $200,896,344.58 in the prior period[24] - The ending balance of cash and cash equivalents stood at $79,655,105.48, significantly higher than $47,944,359.60 from the previous period[24] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥846,107,210.40, down 2.01% from ¥863,485,234.50 at the end of the previous year[4] - Current assets decreased to CNY 444,762,411.59 from CNY 458,436,768.88, indicating a decline of approximately 2.9%[16] - The total liabilities of the company as of March 31, 2025, were CNY 127,437,036.38, compared to CNY 125,619,973.03 at the beginning of the period[16] - Total liabilities increased slightly to ¥156,797,876.21 from ¥155,622,128.21, showing a marginal rise of about 0.8%[19] - The total equity attributable to shareholders decreased to ¥681,161,935.57 from ¥699,659,442.36, a decline of approximately 2.6%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,629[9] - The largest shareholder, Wang Ningyu, holds 28.62% of the shares, amounting to 36,069,811 shares, with 27,052,358 shares pledged[9] - The company reported a total of 43,614,451 shares under lock-up agreements, with 5,404,853 shares released during the period[13] - The number of shares held by the top 10 shareholders was significant, with the largest shareholder holding 9,017,453 shares[12] Operating Expenses - Sales expenses increased by 41.56% to ¥35,058,141.07, primarily due to increased market investment and maintenance costs[7] - Total operating costs slightly increased to ¥86,653,651.22 from ¥86,636,436.82, with operating costs specifically decreasing to ¥24,692,282.96 from ¥29,912,167.64, a reduction of about 17.5%[19] - Research and development expenses rose to ¥8,829,562.22 from ¥7,677,023.64, reflecting an increase of about 15.0% year-over-year[19] Investment and Income - The company reported a significant increase in investment income, which rose by 703.14% to ¥683,600.98 compared to ¥85,115.95 in Q1 2024[7] - The company recorded a total of ¥300,618.72 in non-recurring gains and losses for the reporting period[5] Other Information - The first quarter report was not audited, indicating a potential area of concern for investors[24] - The company will implement new accounting standards starting in 2025, which may affect financial reporting[24] - The company's short-term borrowings increased to CNY 58,344,832.64 from CNY 48,444,832.64, reflecting a rise of approximately 20%[16] - Accounts receivable slightly increased to CNY 159,878,195.76 from CNY 156,838,960.88, showing a growth of about 1.3%[15] - The company's long-term equity investments decreased slightly from CNY 52,393,867.86 to CNY 51,669,435.37, a decline of about 1.4%[16] - The company has not disclosed any new product developments or market expansion strategies in the current report[14]